Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-dose immunomodulatory radiotherapy plus tislelizumab and nab-paclitaxel/carboplatin conversion therapy for locally advanced potentially or borderline resectable ESCC
ChiCTR2400083999Phase 2Not yet recruiting
- Sponsor
- Nanjing Drum-Tower Hospital
- Start
- May 2024
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tislelizumab, paclitaxel and carboplatin in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by Nanjing Drum-Tower Hospital. Primary endpoint: Complete resection rate (R0). Planned start May 2024; status: not yet recruiting.
02
Drugs
tislelizumabpaclitaxelcarboplatin
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on ChiCTR2400083999.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400083999.